Novartis wins European approval for Jakavi
This article was originally published in Scrip
Executive Summary
Novartis has won approval from the European Commission for its JAK inhibitor Jakavi (ruxolitinib) to treat myelofibrosis. The news follows a positive opinion from the CHMP in April this year (scripintelligence.com, 20 April 2012).